Buy SLU-PP-332 Online

SLU-PP-332 is a synthetic small-molecule compound that functions as a potent agonist of estrogen-related receptors (ERRs), particularly ERRα, with moderate activity at ERRβ and ERRγ. It has been studied primarily in preclinical models for its potential to mimic the effects of exercise, improve metabolic health, and counteract age-related mitochondrial dysfunction.

🔬 Chemical Profile

• Chemical Name: 4-hydroxy-N-[(Z)-naphthalen-2-ylmethylideneamino]benzamide

• CAS Number: 303760-60-3

• Molecular Formula: C₁₈H₁₄N₂O₂

• Mechanism of Action: Activates ERRα, ERRβ, and ERRγ, leading to enhanced mitochondrial biogenesis and energy metabolism

⚙️ Mechanism of Action

SLU-PP-332 binds to the ligand-binding domain of ERRα, stabilizing its active conformation and enhancing its interaction with coactivator proteins, particularly PGC-1α. This activation leads to:

• Increased mitochondrial biogenesis and oxidative phosphorylation

• Enhanced fatty acid uptake and β-oxidation

• Stimulation of AMPK signaling, mimicking energy-deprived cellular states

🧪 Preclinical Findings

Studies in rodent models have demonstrated several promising effects:

• Metabolic Syndrome and Obesity: SLU-PP-332 administration resulted in an 18–24% reduction in body weight, a 30–35% decrease in white adipose tissue mass, and a 40% improvement in glucose tolerance.

• Exercise Mimetic Properties: The compound increased mitochondrial density in skeletal muscle, enhanced expression of GLUT4 glucose transporters, and improved muscular endurance and running capacity by 30–40%

• Mitochondrial Dysfunction and Aging: Treatment reversed mitochondrial dysfunction and inflammation in aging tissues, restoring mitochondrial respiration rates and reducing age-associated inflammation markers

• Cardiac Function: SLU-PP-332 preserved cardiac contractility following ischemic insult and improved myocardial energetics through enhanced fatty acid oxidation

🧠 Potential Therapeutic Applications

While SLU-PP-332 has not entered human clinical trials as of 2025, its preclinical efficacy suggests potential applications in:

• Type 2 diabetes and metabolic syndrome

• Sarcopenia and age-related muscle decline

• Mitochondrial disorders

• Neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease